OVID - Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data
Since my last article on Ovid Therapeutics (OVID) the stock has increased almost 5-fold, breaking through the $9 ceiling at one point. Just last week, the stock saw some strong surge before what turned out to be successful phase 2 data from a drug called soticlestat in children with Dravet syndrome ((DS)) or Lennox-Gastaut syndrome (LGS), rare, treatment-resistant, severe forms of epilepsy. This drug is being developed in a 50-50 collaboration with the Japanese giant Takeda Pharmaceutical (TAK).
Besides that, Ovid's lead drug candidate, and the topic of my slightly negative